Halozyme Therapeutics (HALO) Falls Short of Q4 Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $115.13 +3.30%
Revenue Growth %: +36.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: +36.2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
- Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
